Potential for additional government spending on HIV/AIDS in 137 low-income and middle-income countries: an economic modelling study

被引:34
|
作者
Haakenstad, Annie [1 ]
Moses, Mark W. [2 ]
Tao, Tianchan [2 ]
Tsakalos, Golsum [2 ]
Zlavog, Bianca [2 ]
Kates, Jennifer [3 ]
Wexler, Adam [3 ]
Murray, Christopher J. L. [2 ]
Dieleman, Joseph L. [2 ]
机构
[1] Harvard Univ, Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA
[2] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98121 USA
[3] Kaiser Family Fdn, San Francisco, CA USA
来源
LANCET HIV | 2019年 / 6卷 / 06期
基金
比尔及梅琳达.盖茨基金会;
关键词
SYSTEMATIC ANALYSIS; GLOBAL BURDEN; HEALTH; DISEASE;
D O I
10.1016/S2352-3018(19)30038-4
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Between 2012 and 2016, development assistance for HIV/AIDS decreased by 20.0%; domestic financing is therefore critical to sustaining the response to HIV/AIDS. To understand whether domestic resources could fill the financing gaps created by declines in development assistance, we aimed to track spending on HIV/AIDS and estimated the potential for governments to devote additional domestic funds to HIV/AIDS. Methods We extracted 8589 datapoints reporting spending on HIV/AIDS. We used spatiotemporal Gaussian process regression to estimate a complete time series of spending by domestic sources (government, prepaid private, and out-of-pocket) and spending category (prevention, and care and treatment) from 2000 to 2016 for 137 low-income and middle-income countries (LMICs). Development assistance data for HIV/AIDS were from Financing Global Health 2018, and HIV/AIDS prevalence, incidence, and mortality were from the Global Burden of Disease study 2017. We used stochastic frontier analysis to estimate potential additional government spending on HIV/AIDS, which was conditional on the current government health budget and other finance, economic, and contextual factors associated with HIV/AIDS spending. All spending estimates were reported in 2018 US$. Findings Between 2000 and 2016, total spending on HIV/AIDS in LMICs increased from $4.0 billion (95% uncertainty interval 2.9-6.0) to $19.9 billion (15.8-26.3), spending on HIV/AIDS prevention increased from $596 million (258 million to 1.3 billion) to $3.0 billion (1.5-5.8), and spending on HIV/AIDS care and treatment increased from $1.1 billion (458.1 million to 2.2 billion) to $7.2 billion (4.3-11.8). Over this time period, the share of resources sourced from development assistance increased from 33.2% (21.3-45.0) to 46.0% (34.2-57.0). Care and treatment spending per year on antiretroviral therapy varied across countries, with an IQR of $284-2915. An additional $12.1 billion (8.4-17.5) globally could be mobilised by governments of LMICs to finance the response to HIV/AIDS. Most of these potential resources are concentrated in ten middle-income countries (Argentina, China, Colombia, India, Indonesia, Mexico, Nigeria, Russia, South Africa, and Vietnam). Interpretation Some governments could mobilise more domestic resources to fight HIV/AIDS, which could free up additional development assistance for many countries without this ability, including many low-income, high-prevalence countries. However, a large gap exists between available financing and the funding needed to achieve global HIV/AIDS goals, and sustained and coordinated effort across international and domestic development partners is required to end AIDS by 2030. Copyright (C) 2019 The Author(s). Published by Elsevier Ltd.
引用
收藏
页码:E382 / E395
页数:14
相关论文
共 50 条
  • [41] Screening and diagnosis of HBV in low-income and middle-income countries
    Jean-Pierre Allain
    Ohene Opare-Sem
    Nature Reviews Gastroenterology & Hepatology, 2016, 13 : 643 - 653
  • [42] Tobacco control funding for low-income and middle-income countries in a time of economic hardship
    Stoklosa, Michal
    Ross, Hana
    TOBACCO CONTROL, 2014, 23 (E2) : e122 - e126
  • [43] Mental health services in low-income and middle-income countries
    Jacob, K. S.
    LANCET PSYCHIATRY, 2017, 4 (02): : 87 - 89
  • [44] Prevention of underage drinking in low-income and middle-income countries
    Assanangkornchai, Sawitri
    Tanaree, Athip
    Wichaidit, Wit
    LANCET CHILD & ADOLESCENT HEALTH, 2018, 2 (06): : 382 - 384
  • [45] Immunisation against influenza in low-income and middle-income countries
    Bhan, Maharaj Kishan
    Sinha, Bireshwar
    LANCET GLOBAL HEALTH, 2019, 7 (07): : E827 - E828
  • [46] Successful local science in low-income and middle-income countries
    Idrovo, Alvaro J.
    LANCET, 2024, 403 (10427): : 615 - 615
  • [47] BMI and diabetes risk in low-income and middle-income countries
    Choukem, Simeon Pierre
    Dimala, Christian Akem
    LANCET, 2021, 398 (10296): : 190 - 192
  • [48] Guided growth implants for low-income to middle-income countries
    Jamil, Kamal
    Rashid, A. H. Abdul
    Ibrahim, Sharaf
    JOURNAL OF PEDIATRIC ORTHOPAEDICS-PART B, 2013, 22 (06): : 608 - 608
  • [49] Neurocritical Care Organization in the Low-Income and Middle-Income Countries
    Prabhakar, Hemanshu
    Lele, Abhijit V.
    Kapoor, Indu
    Mahajan, Charu
    Shrestha, Gentle S.
    Rao, Chethan Venkatasubba
    Suarez, Jose I.
    Livesay, Sarah L.
    Shafiq, Faraz
    Popugaev, Konstantin
    Santosa, Dhania
    Zada, Obaidullah Naby
    Yang, Wanning
    Nisha, Hosne Ara
    Mijangos-Mendez, Julio C.
    Agaba, Peter Kaahwa
    Portilla, Juan Luis Pinedo
    Tuahir, Yalew Hasen
    Shanmugam, Puvanendiran
    Arruebarrena, Yanet Pina
    Videtta, Walter
    Vasquez-Garcia, Sebastian
    Raheem, M. Samy Abdel
    Yimer, Fasika
    Padayachy, Llewellyn C.
    Naranjo, Luis Silva
    Arriaga, Pedro
    Myei, Chann
    Matuja, Sarah Shali
    Fadalla, Tarig
    Viarasilpa, Tanuwong
    Lundeg, Ganbold
    Salisu-Kabara, Halima M.
    Tsan, Samuel Ern Hung
    Gutierrez, Simon P.
    Yankae, Leroy P.
    Konkayev, Aidos
    Chaikittisilpa, Nophanan
    Sampaio, Gisele
    Bui, Tuan Van
    Mariano, Geraldine Seina L.
    Sabillon, Gisselle Aguilar
    Blanco, Pablo
    Ortiz, Williams
    Gallardo, Angel Jesus Lacerda
    Arun, Oguzhan
    Mani, Kalaivani
    NEUROCRITICAL CARE, 2025,
  • [50] Anal cancer screening in low-income and middle-income countries
    Blair, Kevin J.
    Liliana Valderrama-Beltran, Sandra
    Bautista-Arredondo, Sergio
    Juillard, Catherine
    Lombana Amaya, Luis Jorge
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (07): : 526 - 526